ClinicalTrials.gg
TerminatedNCT03320642Updated Oct 21, 2025

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

A Phase 1 interventional study of Itacitinib and Calcineurin inhibitor in Hematologic Malignancies, sponsored by Incyte Corporation. Terminated at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Prevention

Why this study was terminated
Study terminated by sponsor

From the registry’s dates

  • Primary completion was Feb 2021, 5 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 823 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 277 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Enrollment
176th of 660
84 · median 40
Started
2018
with 24 others
Phase 1
197 of 823
37 open now
Registered
397th of 823
by date

Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 176th largest by enrollment of the 660 interventional ones that give a count, is one of 25 that started in 2018, is one of 197 in phase 1, and was the 397th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 423 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 210 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 823 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).

03

Conditions studied

  • Hematologic Malignancies

Keywords

  • Acute leukemia
  • chronic myelogenous leukemia
  • myelodysplasia
  • chronic lymphocytic leukemia/small lymphocytic lymphoma
  • follicular
  • marginal zone
  • diffuse large B-cell
  • Hodgkin's lymphoma
  • mantle cell lymphoma
  • Janus kinase inhibitor
  • graft-versus-host disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with acute leukemia, chronic myelogenous leukemia, or myelodysplasia with no circulating blasts and \< 5% blasts in the bone marrow.
  • Subjects with non-Hodgkin lymphoma, including but not limited to chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular, marginal zone, diffuse large B cell, or mantle cell lymphoma must have chemosensitive disease at time of transplant. Subjects with Hodgkin lymphoma with chemosensitive disease at the time of transplant.
  • Must be candidates for reduced-intensity conditioning regimens.
  • Must be candidates for peripheral blood stem cell transplants.
  • Performance Status score ≥ 70% or Performance Status score of 0 to 2.
  • Serum creatinine ≤ 2.0 mg/dL or ≥ 40 mL/min measured or calculated by Cockcroft-Gault equation.
  • Be willing to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • Has previously received an allogenic hematopoietic stem cell transplant.
  • Presence of an active uncontrolled infection.
  • Known infection.
  • Active virus (HBV) or virus (HCV) infection that requires treatment or at risk for HBV reactivation.
  • Prior .
  • Severe organ dysfunction.
  • Prior treatment with a JAK inhibitor or with an agent, device, or procedure within 21 days of enrollment.
  • Currently breastfeeding.
  • Known allergies, , or intolerance to any of the study medications.
  • Receipt of live (including attenuated) vaccines during the study, or anticipation of need for such a vaccine during the study.
  • History of primary idiopathic myelofibrosis or any severe marrow fibrosis that would prolong neutrophil engraftment to > 28 days after transplant.
  • Post-transplant maintenance therapy for the hematologic malignancy or plans to initiate maintenance therapy during study treatment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions

    Itacitinib in combination with a CNI-based intervention.

    Drug: Itacitinib · Drug: Calcineurin inhibitor

Interventions

  • Itacitinib administered orally once daily at the protocol-defined dose.

    Also known as: INCB039110

  • DrugCalcineurin inhibitor

    The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate, cyclosporine A/mycophenolate mofetil or tacrolimus plus post-treatment cyclophosphamide. Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with hematologic recovery when itacitinib is added to GVHD prophylaxis treatment

    Hematologic recovery defined as demonstrating both neutrophil recovery (ANC ≥ 500/mm\^3 for 3 consecutive measurements) and platelet recovery (platelet count ≥ 20,000/mm\^3 with no requirement for platelet transfusion in the preceding 3 days).

    Time frame: Day 28

Secondary outcomes

  1. GVHD relapse-free survival rate

    Defined as the proportion of subjects who do not experience Grade III-IV acute GVHD (aGVHD), chronic GVHD (cGVHD) requiring systemic therapy, malignancy relapse or progression, or death due to any cause.

    Time frame: Days 100, 180 and 365

  2. Relapse-free survival

    Defined as the interval between enrollment and malignancy relapse or progression, or death, whichever occurs first.

    Time frame: Up to 1 year

  3. Transplant-related mortality

    Defined as the proportion of subjects who die due to causes other than malignancy relapse or progression.

    Time frame: Up to 1 year

  4. Median time to neutrophil and platelet engraftment

    Defined as the median time to achieve neutrophil and platelet engraftment.

    Time frame: Up to Day 28

  5. Percentage of participants who achieve neutrophil and platelet engraftment

    Defined as the median time to achieve engraftment and hematologic recovery at prespecified time points.

    Time frame: Up to Day 28

  6. Donor Chimerism

    Time frame: Up to Day 28

  7. Proportion of subjects who are diagnosed with Grade II-IV aGVHD, by each grade and by Grade III/IV

    Measured to assess the incidence of aGVHD.

    Time frame: Days 100 and Days 180

  8. Proportion of subjects who are diagnosed with cGVHD by grade (mild, moderate, or severe)

    Measured to assess the incidence of cGVHD.

    Time frame: Up to 1 year

  9. Infection rate

    Defined as the proportion of subjects who demonstrate an infection and/or cytomegalovirus reactivation.

    Time frame: Up to 1 year

  10. Overall survival

    Defined as the interval between enrollment and death due to any cause.

    Time frame: Up to 1 year

  11. Participants with Grade 3-5 treatment-emergent adverse events (TEAEs)

    TEAE is defined as either an adverse event (AE) reported for the first time or worsening of a pre-existing condition after the first dose of study treatment.

    Time frame: Up to approximately 200 days

07

Study locations

17 sites
  • Anschutz Cancer Pavilion - University of Colorado
    Aurora, Colorado 80045, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • University of Maryland - Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • John Theurer Cancer Center, Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Froedtert Hospital and the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Chru de Lille Hopital Claude Huriez
    Lille, 59037, France
  • Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu
    Nantes, 44093, France
  • Chu Vandoeuvre-Les-Nancy, Hopital Brabois
    Vandœuvre-lès-Nancy, 54500, France
  • Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii (Presidio Papa Giovanni Xxiii)
    Bergamo, 24127, Italy
  • Azienda Ospedaliera San Gerardo Di Monza
    Monza, 20900, Italy
  • Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo
    Pavia, 27100, Italy
  • Hospital Puerta de Hierro
    Majadahonda, 28222, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Feb 2021, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2017
First posted
Oct 25, 2017
StartActual
Feb 27, 2018
Primary completionActual
Feb 25, 2021
CompletionActual
Feb 17, 2022
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03320642
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Oct 25, 2017
Start date
Feb 27, 2018
Primary completion
Feb 25, 2021
Completion
Feb 17, 2022
Last update
Oct 21, 2025

Study contacts

Rodica Morariu-Zamfir, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itacitinib

Start the discussion